Definitive Healthcare (NASDAQ:DH) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Key Points

• Definitive Healthcare reported quarterly EPS of $0.05, beating analysts’ $0.04 estimate by $0.01. However, the company posted a negative net margin of 76.04%.
• Shares fell 2.1% to about $0.70, near the company’s 52-week low of $0.62 and well below its 52-week high of $4.35.
• Institutional investors own 98.67% of the stock, while analysts maintain a broadly negative outlook: the consensus rating is “Reduce,” with an average price target of $1.88.

Definitive Healthcare (NASDAQ:DH - Get Free Report) released its quarterly earnings data on Monday. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.01, FiscalAI reports. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.

Definitive Healthcare Trading Down 2.1%

Shares of DH stock traded down $0.01 during trading hours on Monday, hitting $0.70. 172,013 shares of the company were exchanged, compared to its average volume of 358,310. The company has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.12. The firm has a market cap of $73.71 million, a P/E ratio of -0.43, a P/E/G ratio of 11.51 and a beta of 1.35. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.75 and a current ratio of 1.75. Definitive Healthcare has a fifty-two week low of $0.62 and a fifty-two week high of $4.35.

Hedge Funds Weigh In On Definitive Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in DH. BNP Paribas Financial Markets lifted its stake in shares of Definitive Healthcare by 32.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company's stock valued at $72,000 after buying an additional 4,407 shares in the last quarter. Invesco Ltd. raised its holdings in Definitive Healthcare by 5.8% during the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company's stock valued at $337,000 after acquiring an additional 6,400 shares during the period. Raymond James Financial Inc. bought a new stake in Definitive Healthcare during the 2nd quarter valued at $32,000. Creative Planning lifted its position in shares of Definitive Healthcare by 41.7% during the second quarter. Creative Planning now owns 28,628 shares of the company's stock worth $112,000 after acquiring an additional 8,428 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Definitive Healthcare in the fourth quarter worth $35,000. Institutional investors own 98.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DH. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Wall Street Zen raised shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a report on Sunday, July 26th. Robert W. Baird set a $1.10 price target on shares of Definitive Healthcare in a research report on Friday, May 8th. Bank of America reaffirmed an "underperform" rating and set a $0.70 price target on shares of Definitive Healthcare in a research note on Monday, June 29th. Finally, Zacks Research raised shares of Definitive Healthcare from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Hold rating and four have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average target price of $1.88.

Definitive Healthcare Company Profile

Definitive Healthcare NASDAQ: DH is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company's flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source